Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of ...

Pfizer's built from many pieces that are moving in opposite directions. To make sure this stock isn't a yield trap destined to slash its dividend payout in the near term, let's weigh the good news ...

Shares of Pfizer offer a yield above 7% at recent prices. Pfizer is a pharmaceutical giant that has raised its dividend every year since 2009. Loss of patent-protected exclusivity for several ...

At recent prices, the yield you receive from Pfizer is more than four times the amount you'd receive from the average dividend payer in the S&P 500.If it can't maintain its payout-raising streak ...

The past three years have been challenging for Pfizer (PFE -0.52%). Revenue and earnings have moved in the wrong direction, as has the company's share price. The stock is down by 56% since 2022 ...

Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) have gained a positive opinion from the European Medicines Agency’s Committee ...

Is Pfizer stock a buy? Analysis of Pfizer's COVID treatment revenue decline, expiring drug patents, and the need for a blockbuster drug. Is it a good value stock? Donald Trump issues warning to ...

Shares of Pfizer Inc. PFE slipped 1.15% to $23.12 Thursday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 0.53% to 5,939.30 and ...

Detailed price information for Novartis Ag ADR (NVS-N) from The Globe and Mail including charting and trades.